TI
DSGN icon

Trexquant Investment’s Design Therapeutics DSGN Stock Holding History

Trexquant Investment’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25M Buy
117,111
+17,144
+17% +$173K 0.01% 1155
2025
Q4 		$938K Buy
+99,967
New +$783K 0.01% 1202
2023
Q3 		– Sell
-46,524
Closed -$293K – 1540
2023
Q2 		$293K Sell
46,524
-4,315
-8% -$26.4K 0.01% 1204
2023
Q1 		$293K Buy
+50,839
New +$380K 0.01% 1212
2022
Q4 		– Sell
-11,296
Closed -$189K – 1442
2022
Q3 		$189K Buy
+11,296
New +$225K 0.01% 1204

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Trexquant Investment's DSGN Position: Q1 2026 in Review

Trexquant Investment increased its Design Therapeutics (DSGN) stake by 17% in Q1 2026, buying an estimated $173K and bringing the position to 117,111 shares worth $1.25M. The position accounts for 0.01% of the portfolio, ranked #1155.

Trexquant Investment first reported a position in DSGN in Q3 2022 and has held it in 5 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Trexquant Investment held 117,111 shares of Design Therapeutics worth $1.25M as of Q1 2026.
  • Trexquant Investment bought 17,144 Design Therapeutics shares in Q1 2026, an estimated $173K.
  • Design Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q1 2026, its #1155 holding.
  • Trexquant Investment first reported a position in Design Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.